VC-backed Revance Therapeutics files for IPO - Fortune

Fortune has reported that Revance Therapeutics has filed for an $86.25 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol "RVNC." Cowen & Co. and Piper Jaffray will serve as lead underwriters. Based in Newark, California, Revance is a biopharmaceutical company that is providing solutions for the way drugs are delivered. Its backers include Essex Woodlands Health Ventures, NovaQuest Capita, Technology Partners, Vivo Ventures, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corp.

North AmericaUSBriefs